ANALLISA

PHASE II STUDY TO ASSESS THE EFFICACY OF NIRAPARIB RECHALLENGE AFTER SURGERY IN OVARIAN CANCER PATIENTS WITH OLIGOMETASTATIC PROGRESSION (THE ANALLISA STUDY)

THE PRIMARY OBJECTIVE IS TO EVALUATE PROGRESSION-FREE SURVIVAL (PFS) OF NIRAPARIB RECHALLENGE IN OC PATIENTS WITH OMP AND NO RESIDUAL DISEASE AFTER SECONDARY CYTOREDUCTIVE SURGERY.

https://clinicaltrials.gov/study/NCT06180356

COUNTRY

STATUS

TUMOR TYPE

PHASE

SITES

Endometrioid Ovarian Cancer

Spain

Recruitment

CLINICAL TRIAL DETAILS

PRESS RELEASE

SCIENTIFIC IMPACT

IGCS 2024 presentation: https://www.medsir.org/_files/ugd/39f166_1186e5c7696c40ea8f13e481b1864410.pdf

BLOG ARTICLES RELATED

TRIAL SITES

Hospital Universitario Ramón y Cajal (Spain) | Hospital Universitario Jaén (Spain) | Hospital Universitario La Paz (Spain) | Vall d'Hebron Institute of Oncology (Spain) | Hospital Universitario San Juan de Reus (Spain) | Hospital Universitario 12 de Octubre (Spain) | Hospital Universitario de A Coruña (CHUAC) (Spain) | Hospital Universitario Virgen Macarena (Spain) | Hospital Arnau de Vilanova de Valencia (Spain)

Dr. Cortes and Dr. Llombart PHERain interview

Beyond Chemotherapy

Dr. Vanes Quiroga

Dr. Sofia Braga

Dr. Silvi Antolín

Dr. Escrivá de Romaní

Dr. Philipp Aftimos

Dr. Manuel Ruiz

Prof. Daniele Generali PHEGain interview

Dr. Jacques Medioni

Dr. Dunca Wheatley